Protagonist Therapeutics (NASDAQ:PTGX) vs. TransCode Therapeutics (NASDAQ:RNAZ) Financial Survey

TransCode Therapeutics (NASDAQ:RNAZ) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares TransCode Therapeutics and Protagonist Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Volatility and Risk

TransCode Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.

Institutional and Insider Ownership

98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for TransCode Therapeutics and Protagonist Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1	0	0	0	1.00
Protagonist Therapeutics	0	2	15	1	2.94

Protagonist Therapeutics has a consensus target price of $140.53, suggesting a potential downside of 8.93%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than TransCode Therapeutics.

Earnings and Valuation

This table compares TransCode Therapeutics and Protagonist Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66 million	($52.37)	-0.05
Protagonist Therapeutics	$281.99 million	35.41	-$130.15 million	$1.03	149.83

TransCode Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats TransCode Therapeutics on 13 of the 14 factors compared between the two stocks.

About TransCode Therapeutics

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.